52 related articles for article (PubMed ID: 29649923)
1. Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Roar M; Nielsen ARH; Berg JM; Sirakov G; Stilund M; Schäfer J; Ratzer R; Frederiksen J; Asgari N; Ashna SN; Jensen HB; Kant M; Theódorsdóttir Á; Illes Z; Sellebjerg F; Magyari M; Schlosser LM; Nordborg H; Wergeland S; Sejbaek T
Mult Scler Relat Disord; 2023 Dec; 80():105127. PubMed ID: 37956521
[TBL] [Abstract][Full Text] [Related]
2. Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
Elkjaer ML; Lohse RM; Burton M; Mendoza JP; Thomassen M; Sejbaek T; Illes Z
J Neuroimmunol; 2023 Aug; 381():578145. PubMed ID: 37393851
[TBL] [Abstract][Full Text] [Related]
3. New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.
Schneider M; Kramer J; Banks A; Moses H
Mult Scler; 2024 Apr; ():13524585241242027. PubMed ID: 38605496
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
[TBL] [Abstract][Full Text] [Related]
5. A probiotic modulates the microbiome and immunity in multiple sclerosis.
Tankou SK; Regev K; Healy BC; Tjon E; Laghi L; Cox LM; Kivisäkk P; Pierre IV; Hrishikesh L; Gandhi R; Cook S; Glanz B; Stankiewicz J; Weiner HL
Ann Neurol; 2018 Jun; 83(6):1147-1161. PubMed ID: 29679417
[TBL] [Abstract][Full Text] [Related]
6. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
Vavasour IM; Tam R; Li DK; Laule C; Taylor C; Kolind SH; MacKay AL; Javed A; Traboulsee A
Mult Scler; 2019 May; 25(6):811-818. PubMed ID: 29663845
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary extensively drug-resistant tuberculosis in Melbourne: local control of a global health challenge.
Tramontana AR; Leslie DE; Nolan A; Globan M; Fyfe JM; Denholm JT; Guy SD
Med J Aust; 2018 Jun; 208(10):428-429. PubMed ID: 29848244
[No Abstract] [Full Text] [Related]
8. Progressive multifocal leukoencephalopathy after fingolimod treatment.
Berger JR; Cree BA; Greenberg B; Hemmer B; Ward BJ; Dong VM; Merschhemke M
Neurology; 2018 May; 90(20):e1815-e1821. PubMed ID: 29669908
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal immunoglobulin M production: A promising high-risk marker in clinically isolated syndrome patients.
Huss A; Abdelhak A; Halbgebauer S; Mayer B; Senel M; Otto M; Tumani H
Ann Neurol; 2018 May; 83(5):1032-1036. PubMed ID: 29665046
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Major EO; Yousry TA; Clifford DB
Lancet Neurol; 2018 May; 17(5):467-480. PubMed ID: 29656742
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient.
Perini P; Rinaldi F; Puthenparampil M; Marcon M; Perini F; Gallo P
Mult Scler Relat Disord; 2018 Nov; 26():68-70. PubMed ID: 30227312
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate associated lymphopenia in clinical practice.
Longbrake EE; Cross AH
Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
[No Abstract] [Full Text] [Related]
14. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
16. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
[TBL] [Abstract][Full Text] [Related]
17. Diffuse dermatophytosis occurring on dimethyl fumarate therapy.
Greenstein JI
Mult Scler; 2018 Jun; 24(7):999-1001. PubMed ID: 29649923
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
